Literature DB >> 3422447

Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells.

K J Scanlon1, M Kashani-Sabet.   

Abstract

Activity of the thymidylate synthase cycle was compared in the human ovarian carcinoma cell line A2780 and a subline that is resistant to cisplatin by a factor of 3. Resistant cells exhibited a 3-fold increase in mRNA for both dihydrofolate reductase (5,6,7,8-tetrahydrofolate:NADP+-oxidoreductase, EC 1.5.1.3) and thymidylate synthase (5,10-methylenetetrahydrofolate:dUMP C-methyltransferase, EC 2.1.1.45) when compared with the parent line. Resistance to cisplatin also resulted in a 2.5-fold increase in enzyme activity for dihydrofolate reductase and thymidylate synthase; however, this increase did not result from amplification of the genes for these two enzymes. These data suggest that the initial step of cisplatin resistance in A2780 cells is a consequence of enhanced expression of the thymidylate synthase cycle.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3422447      PMCID： PMC279612          DOI： 10.1073/pnas.85.3.650

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  19 in total

1.  A rapid, radiochemical-ligand binding assay for methotrexate.

Authors:  B A Kamen; P L Takach; R Vatev; J D Caston
Journal:  Anal Biochem       Date:  1976-01       Impact factor: 3.365

Review 2.  Chemotherapy of ovarian cancer.

Authors:  R F Ozols; R C Young
Journal:  Semin Oncol       Date:  1984-09       Impact factor: 4.929

3.  Multiple forms of human dihydrofolate reductase messenger RNA. Cloning and expression in Escherichia coli of their DNA coding sequence.

Authors:  C Morandi; J N Masters; M Mottes; G Attardi
Journal:  J Mol Biol       Date:  1982-04-15       Impact factor: 5.469

4.  A rapid radiometric assay for dihydrofolate reductase.

Authors:  R Hayman; R McGready; M B Van der Weyden
Journal:  Anal Biochem       Date:  1978-07-01       Impact factor: 3.365

5.  Isolation of a cDNA clone for human X-linked 3-phosphoglycerate kinase by use of a mixture of synthetic oligodeoxyribonucleotides as a detection probe.

Authors:  J Singer-Sam; R L Simmer; D H Keith; L Shively; M Teplitz; K Itakura; S M Gartler; A D Riggs
Journal:  Proc Natl Acad Sci U S A       Date:  1983-02       Impact factor: 11.205

6.  Inhibition of methionine uptake by methotrexate in mouse leukemia L1210 cells.

Authors:  K J Scanlon; A R Cashmore; M Kashani-Sabet; M Pallai; R N Dreyer; B A Moroson; M Saketos
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Inhibition of methionine transport by methotrexate in mitogen-stimulated human lymphocytes.

Authors:  K J Scanlon; K Berkowitz; M E Pallai; S Waxman
Journal:  Cancer Treat Rep       Date:  1983 Jul-Aug

8.  Inhibition of amino acid transport by cis-diamminedichloroplatinum(II) derivatives in L1210 murine leukemia cells.

Authors:  K J Scanlon; R L Safirstein; H Thies; R B Gross; S Waxman; J B Guttenplan
Journal:  Cancer Res       Date:  1983-09       Impact factor: 12.701

9.  Regulation of thymidylate synthetase in mouse leukemia cells (L1210).

Authors:  W Rode; K J Scanlon; B A Moroson; J R Bertino
Journal:  J Biol Chem       Date:  1980-02-25       Impact factor: 5.157

Review 10.  Establishment of cross-resistance profiles for new agents.

Authors:  F M Schabel; H E Skipper; M W Trader; W R Laster; D P Griswold; T H Corbett
Journal:  Cancer Treat Rep       Date:  1983-10
View more
  18 in total

1.  Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein.

Authors:  K J Scanlon; L Jiao; T Funato; W Wang; T Tone; J J Rossi; M Kashani-Sabet
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

2.  Ribozyme-mediated reversal of the multidrug-resistant phenotype.

Authors:  K J Scanlon; H Ishida; M Kashani-Sabet
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

3.  Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase.

Authors:  Daniela Cardinale; Giambattista Guaitoli; Donatella Tondi; Rosaria Luciani; Stefan Henrich; Outi M H Salo-Ahen; Stefania Ferrari; Gaetano Marverti; Davide Guerrieri; Alessio Ligabue; Chiara Frassineti; Cecilia Pozzi; Stefano Mangani; Dimitrios Fessas; Remo Guerrini; Glauco Ponterini; Rebecca C Wade; M Paola Costi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-27       Impact factor: 11.205

4.  Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines.

Authors:  W Zhen; C J Link; P M O'Connor; E Reed; R Parker; S B Howell; V A Bohr
Journal:  Mol Cell Biol       Date:  1992-09       Impact factor: 4.272

5.  Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA.

Authors:  G Chu; E Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

6.  Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors.

Authors:  D Chatterjee; C J Liu; D Northey; B A Teicher
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Presence and possible significance of immunocytochemically demonstrable metallothionein over-expression in primary invasive ductal carcinoma of the breast.

Authors:  K W Schmid; I O Ellis; J M Gee; B M Darke; W E Lees; J Kay; A Cryer; J M Stark; A Hittmair; D Ofner
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

8.  Relationship between folate-binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines.

Authors:  F Ottone; S Miotti; C Bottini; M Bagnoli; P Perego; M I Colnaghi; S Ménard
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Mechanisms of collateral sensitivity to fluorouracil of a cis-diamminedichloroplatinum(II)-resistant human non-small lung cancer cell line.

Authors:  Y Sugimoto; Y Ohe; K Nishio; T Ohmori; T Morikage; Y Fujiwara; N Saijo
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

10.  Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes.

Authors:  D W Shen; S Akiyama; P Schoenlein; I Pastan; M M Gottesman
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.